A team investigating preterm birth has turned to a simple, controllable delivery-room variable: how long clinicians delay clamping the umbilical cord. In a retrospective, single-center cohort study spanning gestational ages 23–35 weeks, researchers asked whether the duration of delayed cord clamping (DCC) can forecast two clinically important outcomes—hyperbilirubinemia and the number of days a newborn requires phototherapy.
The study’s premise is grounded in neonatal physiology. After birth, red blood cells continue to break down, generating bilirubin. DCC increases the infant’s immediate blood volume and iron stores by allowing more placental transfusion, but that same extra erythrocyte load could plausibly raise bilirubin production. The key question is whether longer DCC durations translate into more days of treatment or higher bilirubin exposure across different degrees of prematurity.
To address this, investigators linked DCC timing to subsequent clinical records, stratifying infants by gestational age and tracking phototherapy days. The design emphasized real-world practice patterns, using existing documentation rather than assigning interventions prospectively—an approach that accelerates evidence generation but also requires careful statistical adjustment for confounders.
Results indicate that gestational age modifies the relationship between DCC duration and bilirubin-related burden. In other words, the same DCC duration may not carry identical implications for infants at 23–25 weeks versus those closer to term. The findings help refine the idea of “one-size-fits-all” timing, suggesting that clinicians may need to interpret DCC duration through the lens of developmental maturity.
From a public-health perspective, the study matters because phototherapy is not trivial: it increases handling, prolongs care in neonatal intensive settings, and can affect workflow and family bonding. Even when bilirubin levels remain within safety thresholds, repeated or extended phototherapy reflects greater clinical vigilance.
Importantly, the analysis does not simply ask whether DCC was used, but whether how long it was used predicts downstream treatment. That distinction could guide unit protocols that currently standardize by categorical timing rather than modeling bilirubin risk as a dose-like exposure.
The authors argue that tailoring DCC duration by gestational-age group may better balance benefits such as improved circulatory transition against the likelihood of bilirubin escalation. If confirmed in larger, prospective studies, the work could influence guideline-level recommendations and delivery-room decision-making.
As clinicians continue to optimize early stabilization strategies for the most vulnerable newborns, this study provides a data-driven step toward more individualized cord-clamping practices. For now, it adds nuance to the ongoing debate over DCC timing by tying duration to phototherapy intensity across the preterm spectrum.
Subject of Research: Delayed umbilical cord clamping duration and bilirubin outcomes in preterm infants (hyperbilirubinemia, phototherapy days).
Article Title: Impact of duration of delayed umbilical cord clamping on days of phototherapy in preterm neonates 23–35 weeks gestation—a retrospective, single-center cohort study.
Article References: Patel, A., Yanowitz, T.D. J Perinatol (2026). https://doi.org/10.1038/s41372-026-02807-6
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41372-026-02807-6
Keywords:
